bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.080
+0.290 (7.65%)
At close: Mar 28, 2025, 4:00 PM
4.450
+0.370 (9.07%)
After-hours: Mar 28, 2025, 7:59 PM EDT
bluebird bio Employees
bluebird bio had 375 employees as of December 31, 2023. The number of employees increased by 52 or 16.10% compared to the previous year.
Employees
375
Change (1Y)
52
Growth (1Y)
16.10%
Revenue / Employee
$223,485
Profits / Employee
-$641,907
Market Cap
39.94M
Employees Chart
Employees History
BLUE News
- 15 days ago - BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE - Business Wire
- 5 weeks ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. - PRNewsWire
- 5 weeks ago - Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC
- 5 weeks ago - bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs - Accesswire
- 5 weeks ago - Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch - Reuters
- 5 weeks ago - bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - Business Wire
- 5 weeks ago - High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models - CNBC
- 3 months ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire